Citalopram/pipamperone - PharmaNeuroBoost
Alternative Names: Pipamperone/citalopram; PipCit; PNB-01Latest Information Update: 01 Sep 2015
At a glance
- Originator PharmaNeuroBoost
- Class Antidepressants; Antipsychotics; Benzofurans; Butyrophenones; Nitriles; Propylamines; Small molecules
- Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 01 Sep 2015 No recent reports on development identified - Phase-III for Major depressive disorder in USA and Canada (PO)
- 01 Sep 2015 No recent reports on development identified - Phase-II for Major depressive disorder in United Kingdom (PO)
- 01 Dec 2012 PharmaNeuroBoost N.V. completes a phase III trial in Major Depressive Disorder in USA and Canada (PO) (NCT01312922)